Black Rock Inc. Aptinyx Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.12 - $0.69 $334 - $1,925	2,790 Added 0.41%	689,982 $82,000
Q4 2022 Feb 13, 2023	BUY	$0.23 - $0.34 $305 - $452	1,330 Added 0.19%	687,192 $199,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.72 $118,908 - $244,612	-339,739 Reduced 33.13%	685,862 $253,000
Q2 2022 Aug 12, 2022	SELL	$0.38 - $2.58 $110,320 - $749,015	-290,316 Reduced 22.06%	1,025,601 $572,000
Q1 2022 May 12, 2022	SELL	$2.27 - $3.62 $133,591 - $213,040	-58,851 Reduced 4.28%	1,315,917 $2.99 Million
Q4 2021 Feb 10, 2022	BUY	$2.11 - $3.0 $44,158 - $62,784	20,928 Added 1.55%	1,374,768 $3.67 Million
Q3 2021 Nov 09, 2021	BUY	$2.21 - $2.89 $7,237 - $9,464	3,275 Added 0.24%	1,353,840 $3.17 Million
Q2 2021 Aug 11, 2021	BUY	$2.39 - $3.5 $3.23 Million - $4.73 Million	1,350,565 New	1,350,565 $3.82 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.